Learn / Stock guides / ABBV vs PFE

Compare

AbbVie vs Pfizer: how do the stocks compare?

ABBV and PFE side by side, in plain English. This is an explanation of the two businesses, not a recommendation to buy either one.

ABBVPFE
TickerABBVPFE
ExchangeNYSENYSE
SectorHealthcareHealthcare
IndustryDrug Manufacturers GeneralDrug Manufacturers General
Sizemega caplarge cap
Market value464.3 billion dollars158.4 billion dollars

AbbVie (ABBV)

AbbVie trades on the New York Stock Exchange under the ticker ABBV. It is a mega cap company in the drug manufacturers general industry, part of the healthcare sector, with a market value of about 464.3 billion dollars.

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

Pfizer (PFE)

Pfizer trades on the New York Stock Exchange under the ticker PFE. It is a large cap company in the drug manufacturers general industry, part of the healthcare sector, with a market value of about 158.4 billion dollars.

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

Follow ABBV and PFE every day

Add both to your watchlist and read a free plain English brief every trading day at 5 PM ET.

Start my free brief

Common questions

What is the difference between ABBV and PFE?

AbbVie trades on the New York Stock Exchange under the ticker ABBV. It is a mega cap company in the drug manufacturers general industry, part of the healthcare sector, with a market value of about 464.3 billion dollars. Pfizer trades on the New York Stock Exchange under the ticker PFE. It is a large cap company in the drug manufacturers general industry, part of the healthcare sector, with a market value of about 158.4 billion dollars.

Which is bigger, AbbVie or Pfizer?

AbbVie has the larger market value, at about 464.3 billion dollars.

Are AbbVie and Pfizer in the same industry?

Yes. Both are in the drug manufacturers general industry.

Educational information, not financial advice. Figures are approximate and do not include live prices.